Immix Biopharma Presents Positive Data on NXC-201 CAR-T Cell Therapy for AL Amyloidosis at IMS Annual Meeting

Immix Biopharma, a clinical-stage biopharmaceutical company, recently presented encouraging clinical data on its novel CAR-T cell therapy, NXC-201, for the treatment of AL Amyloidosis. The data was shared at an oral presentation during the 20th International Myeloma Society Annual Meeting held in Athens, Greece.

AL Amyloidosis is a rare systemic disorder that affects thousands of patients worldwide, causing the abnormal buildup of misfolded amyloid proteins in tissues, nerves, and organs. Currently, there are no approved drugs for relapsed/refractory AL Amyloidosis, making the development of effective treatments crucial.

The Phase 1b/2a NEXICART-1 study evaluated NXC-201 in patients with relapsed/refractory AL Amyloidosis who had previously undergone multiple unsuccessful treatments. The study included nine patients, with one new patient and additional follow-up data from eight patients.

The data presented showed a 100% response rate in relapsed/refractory AL Amyloidosis patients, including those with cardiac involvement and t(11;14) relapsed/refractory AL Amyloidosis. These results indicate a potential broad mechanism of action for NXC-201.

Furthermore, NXC-201 offers the advantage of being a one-time treatment, which could significantly improve the quality of life for patients who currently require repeat dosing and frequent travel to academic medical centers for treatment.

Immix Biopharma’s CEO, Ilya Rachman, highlighted the potential of NXC-201 to fill the void in relapsed/refractory AL Amyloidosis treatment, where no approved therapies currently exist. The therapy’s favorable tolerability profile and ability to clear disease-causing amyloid chains from the body within approximately 30 days make it a promising candidate for outpatient treatment.

The positive clinical data presented at the IMS Annual Meeting further supports the potential of NXC-201 as a personalized therapy for AL Amyloidosis. Immix Biopharma and its subsidiary, Nexcella, are committed to advancing the development of NXC-201 and plan to submit data to the FDA once the required number of patients have been treated.

With the AL Amyloidosis market projected to reach $6 billion by 2025, the success of NXC-201 could have a significant impact on patient outcomes and the overall treatment landscape for this rare disease.

For more information on the NEXICART-1 study and NXC-201, please visit Immix Biopharma’s corporate website.